Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HOGA1 | Q86XE5 | 1/20 | 0.32 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29302102 | 0.89 | HOGA1 (0.34) | ADORA3MEN1KMT2AHOGA1 | |
| SCHEMBL27391612 | 0.86 | ADORA3 (0.31) | ADORA3MEN1KMT2A | |
| SCHEMBL27391516 | 0.85 | HOGA1 (0.35) | ADORA3HOGA1 | |
| SCHEMBL29299804 | 0.82 | FOLH1 (0.37) | — | |
| SCHEMBL29299618 | 0.74 | ADORA3 (0.36) | ADORA3HOGA1 | |
| SCHEMBL29300368 | 0.73 | IDUA (0.36) | ADORA3 | |
| SCHEMBL29302098 | 0.72 | FOLH1 (0.34) | ADORA3MEN1KMT2AHOGA1 | |
| SCHEMBL19784356 | 0.72 | HOGA1 (0.39) | HOGA1LGALS3 | |
| SCHEMBL20888674 | 0.72 | HOGA1 (0.39) | HOGA1LGALS3 | |
| SCHEMBL27391428 | 0.72 | HOGA1 (0.39) | HOGA1LGALS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240226343-A1 | NEUROPEPTIDE Y1 RECEPTOR (NPY1R) TARGETED THERAPEUTICS AND USES THEREOF | RADIONETICS ONCOLOGY, INC. | 2024-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240226343-A1 | NEUROPEPTIDE Y1 RECEPTOR (NPY1R) TARGETED THERAPEUTICS AND USES THEREOF | NPY1R, NPY2R, NPY4R | ADORA3 1203/4885MEN1 601/4885KMT2A 3160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.